#METABOLOMICS WORKBENCH hormel101_20170623_145937 DATATRACK_ID:1100 STUDY_ID:ST000651 ANALYSIS_ID:AN000985 PROJECT_ID:PR000460
VERSION             	1
CREATED_ON             	June 26, 2017, 8:19 am
#PROJECT
PR:PROJECT_TITLE                 	The dystrophic muscle metabolome: effects of exercise and NO donor therapy
PR:PROJECT_SUMMARY               	"In Duchenne and Becker muscular dystrophy (DMD, BMD), loss of the cytoskeletal
PR:PROJECT_SUMMARY               	protein dystrophin weakens the sarcolemma and disrupts cellular signaling,
PR:PROJECT_SUMMARY               	rendering the diseased muscles susceptible to contractioninduced damage. We and
PR:PROJECT_SUMMARY               	others have shown that loss of neuronal nitric oxide synthase (nNOSμ) from the
PR:PROJECT_SUMMARY               	sarcolemma of dystrophin-deficient muscle causes functional muscle ischemia
PR:PROJECT_SUMMARY               	during exercise due to unopposed sympathetic vasoconstriction, thereby
PR:PROJECT_SUMMARY               	exacerbating fatigue and injury of the diseased muscles. Genetic and
PR:PROJECT_SUMMARY               	pharmacologic strategies targeting nNOSμ-NO signaling ameliorate functional
PR:PROJECT_SUMMARY               	muscle ischemia, as well as many other features of the dystrophic phenotype in
PR:PROJECT_SUMMARY               	the mdx mouse model of DMD/BMD. These findings suggest that the therapeutic
PR:PROJECT_SUMMARY               	benefit of NO likely extends beyond its vascular effects. A growing body of
PR:PROJECT_SUMMARY               	evidence indicates that NO directly influences muscle metabolism through effects
PR:PROJECT_SUMMARY               	on glucose transport as well as mitochondrial biogenesis and function. Both
PR:PROJECT_SUMMARY               	nNOS-/- mice and mdx mice exhibit muscle mitochondrial dysfunction, decreased
PR:PROJECT_SUMMARY               	resistance to fatigue, and exercise-induced muscle injury, suggesting a causal
PR:PROJECT_SUMMARY               	role of nNOSμ-NO deficiency. However, the specific metabolic changes resulting
PR:PROJECT_SUMMARY               	from reduced NO signaling that might render dystrophic muscle susceptible to
PR:PROJECT_SUMMARY               	fatigue and use-dependent injury remain poorly defined. Therefore, the goal of
PR:PROJECT_SUMMARY               	this pilot metabolomics study is to identify the unique biochemical profiles of
PR:PROJECT_SUMMARY               	skeletal and cardiac muscles of mdx mice to gain further mechanistic insight
PR:PROJECT_SUMMARY               	into the pathophysiological role of NO deficiency in muscular dystrophy. In Aim
PR:PROJECT_SUMMARY               	1, we will characterize the skeletal and cardiac muscle metabolomes of mdx and
PR:PROJECT_SUMMARY               	nNOS-/- mice at rest and following a single bout of treadmill exercise with the
PR:PROJECT_SUMMARY               	goal of discovering common metabolic signatures caused by loss of NO signaling.
PR:PROJECT_SUMMARY               	In Aim 2, we will evaluate the potential of a NO donor drug that is under
PR:PROJECT_SUMMARY               	development as a therapeutic for DMD/BMD to improve the skeletal and cardiac
PR:PROJECT_SUMMARY               	muscle metabolomes in mdx mice. As a result of this pilot study, we hope to gain
PR:PROJECT_SUMMARY               	new understanding of the metabolic derangements in dystrophin-deficient muscle,
PR:PROJECT_SUMMARY               	insight into the therapeutic effects of NO replacement, and to identify new
PR:PROJECT_SUMMARY               	pathogenic mechanisms and putative therapeutic targets that will form the basis
PR:PROJECT_SUMMARY               	of future grant applications."
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Thomas
PR:FIRST_NAME                    	Gail
PR:ADDRESS                       	Penn State Hershey Heart and Vascular Institute Penn State College of Medicine
PR:ADDRESS                       	500 University Drive, MC H047 Hershey, PA 17033
PR:EMAIL                         	gthomas4@hmc.psu.edu
PR:PHONE                         	717-531-0003, ext. 287087
#STUDY
ST:STUDY_TITLE                   	Effects of NO Donor Therapy on the Dystrophic Mouse Heart Metabolome (part VII)
ST:STUDY_SUMMARY                 	For this aim, we will only use male mdx mice. We will study three groups treated
ST:STUDY_SUMMARY                 	for 7 days with vehicle, naproxcinod (i.e., NO-naproxen), or naproxen (n = 10
ST:STUDY_SUMMARY                 	each group). Two hours after the final treatment, half the mice in each group
ST:STUDY_SUMMARY                 	will be run to exhaustion on a treadmill. The heart and gastrocnemius, soleus,
ST:STUDY_SUMMARY                 	and quadriceps muscles of one hindlimb will be sent to the Mayo Clinic
ST:STUDY_SUMMARY                 	Metabolomics Resource Core. The heart and quadriceps muscle will be used for
ST:STUDY_SUMMARY                 	untargeted metabolomics profiling (LC/MS).
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Thomas
ST:FIRST_NAME                    	Gail
ST:ADDRESS                       	Penn State Hershey Heart and Vascular Institute Penn State College of Medicine
ST:ADDRESS                       	500 University Drive, MC H047 Hershey, PA 17033
ST:EMAIL                         	gthomas4@hmc.psu.edu
ST:PHONE                         	717-531-0003, ext. 287087
#SUBJECT
SU:SUBJECT_TYPE                  	Mouse
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	ms5860-1	nC18-01may16-001-r001	Group:SED-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-1	nC18-01may16-001-r002	Group:SED-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-2	nC18-01may16-002-r001	Group:RUN-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-2	nC18-01may16-002-r002	Group:RUN-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-3	nC18-01may16-003-r001	Group:RUN-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-3	nC18-01may16-003-r002	Group:RUN-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-4	nC18-01may16-004-r001	Group:RUN-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-4	nC18-01may16-004-r002	Group:RUN-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-5	nC18-01may16-005-r001	Group:SED-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-5	nC18-01may16-005-r002	Group:SED-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-6	nC18-01may16-006-r001	Group:RUN-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-6	nC18-01may16-006-r002	Group:RUN-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-7	nC18-01may16-007-r001	Group:SED-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-7	nC18-01may16-007-r002	Group:SED-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-8	nC18-01may16-008-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-8	nC18-01may16-008-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-9	nC18-01may16-009-r001	Group:SED-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-9	nC18-01may16-009-r002	Group:SED-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-10	nC18-01may16-010-r001	Group:SED-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-10	nC18-01may16-010-r002	Group:SED-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-11	nC18-01may16-011-r001	Group:RUN-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-11	nC18-01may16-011-r002	Group:RUN-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-12	nC18-01may16-012-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-12	nC18-01may16-012-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-13	nC18-01may16-013-r001	Group:RUN-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-13	nC18-01may16-013-r002	Group:RUN-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-14	nC18-01may16-014-r001	Group:SED-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-14	nC18-01may16-014-r002	Group:SED-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-15	nC18-01may16-015-r001	Group:SED-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-15	nC18-01may16-015-r002	Group:SED-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-16	nC18-01may16-016-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-16	nC18-01may16-016-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-17	nC18-01may16-017-r001	Group:SED-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-17	nC18-01may16-017-r002	Group:SED-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-18	nC18-01may16-018-r001	Group:RUN-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-18	nC18-01may16-018-r002	Group:RUN-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-19	nC18-01may16-019-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-19	nC18-01may16-019-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-20	nC18-01may16-020-r001	Group:RUN-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-20	nC18-01may16-020-r002	Group:RUN-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-21	nC18-01may16-021-r001	Group:SED-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-21	nC18-01may16-021-r002	Group:SED-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-22	nC18-01may16-022-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-22	nC18-01may16-022-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-23	nC18-01may16-023-r001	Group:RUN-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-23	nC18-01may16-023-r002	Group:RUN-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-24	nC18-01may16-024-r001	Group:RUN-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-24	nC18-01may16-024-r002	Group:RUN-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-25	nC18-01may16-025-r001	Group:SED-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-25	nC18-01may16-025-r002	Group:SED-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-26	nC18-01may16-026-r001	Group:SED-Naproxcinod | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-26	nC18-01may16-026-r002	Group:SED-Naproxcinod | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-27	nC18-01may16-027-r001	Group:SED-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-27	nC18-01may16-027-r002	Group:SED-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-28	nC18-01may16-028-r001	Group:SED-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-28	nC18-01may16-028-r002	Group:SED-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-29	nC18-01may16-029-r001	Group:SED-Vehicle | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-29	nC18-01may16-029-r002	Group:SED-Vehicle | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-30	nC18-01may16-030-r001	Group:SED-Naproxen | rep:1	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-30	nC18-01may16-030-r002	Group:SED-Naproxen | rep:2	chromatography=NC18
SUBJECT_SAMPLE_FACTORS           	ms5860-1	pC18-29apr16-001-r001	Group:SED-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-1	pC18-29apr16-001-r002	Group:SED-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-2	pC18-29apr16-002-r001	Group:RUN-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-2	pC18-29apr16-002-r002	Group:RUN-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-3	pC18-29apr16-003-r001	Group:RUN-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-3	pC18-29apr16-003-r002	Group:RUN-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-4	pC18-29apr16-004-r001	Group:RUN-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-4	pC18-29apr16-004-r002	Group:RUN-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-5	pC18-29apr16-005-r001	Group:SED-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-5	pC18-29apr16-005-r002	Group:SED-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-6	pC18-29apr16-006-r001	Group:RUN-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-6	pC18-29apr16-006-r002	Group:RUN-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-7	pC18-29apr16-007-r001	Group:SED-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-7	pC18-29apr16-007-r002	Group:SED-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-8	pC18-29apr16-008-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-8	pC18-29apr16-008-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-9	pC18-29apr16-009-r001	Group:SED-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-9	pC18-29apr16-009-r002	Group:SED-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-10	pC18-29apr16-010-r001	Group:SED-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-10	pC18-29apr16-010-r002	Group:SED-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-11	pC18-29apr16-011-r001	Group:RUN-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-11	pC18-29apr16-011-r002	Group:RUN-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-12	pC18-29apr16-012-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-12	pC18-29apr16-012-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-13	pC18-29apr16-013-r001	Group:RUN-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-13	pC18-29apr16-013-r002	Group:RUN-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-14	pC18-29apr16-014-r001	Group:SED-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-14	pC18-29apr16-014-r002	Group:SED-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-15	pC18-29apr16-015-r001	Group:SED-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-15	pC18-29apr16-015-r002	Group:SED-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-16	pC18-29apr16-016-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-16	pC18-29apr16-016-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-17	pC18-29apr16-017-r001	Group:SED-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-17	pC18-29apr16-017-r002	Group:SED-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-18	pC18-29apr16-018-r001	Group:RUN-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-18	pC18-29apr16-018-r002	Group:RUN-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-19	pC18-29apr16-019-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-19	pC18-29apr16-019-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-20	pC18-29apr16-020-r001	Group:RUN-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-20	pC18-29apr16-020-r002	Group:RUN-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-21	pC18-29apr16-021-r001	Group:SED-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-21	pC18-29apr16-021-r002	Group:SED-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-22	pC18-29apr16-022-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-22	pC18-29apr16-022-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-23	pC18-29apr16-023-r001	Group:RUN-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-23	pC18-29apr16-023-r002	Group:RUN-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-24	pC18-29apr16-024-r001	Group:RUN-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-24	pC18-29apr16-024-r002	Group:RUN-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-25	pC18-29apr16-025-r001	Group:SED-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-25	pC18-29apr16-025-r002	Group:SED-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-26	pC18-29apr16-026-r001	Group:SED-Naproxcinod | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-26	pC18-29apr16-026-r002	Group:SED-Naproxcinod | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-27	pC18-29apr16-027-r001	Group:SED-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-27	pC18-29apr16-027-r002	Group:SED-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-28	pC18-29apr16-028-r001	Group:SED-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-28	pC18-29apr16-028-r002	Group:SED-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-29	pC18-29apr16-029-r001	Group:SED-Vehicle | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-29	pC18-29apr16-029-r002	Group:SED-Vehicle | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-30	pC18-29apr16-030-r001	Group:SED-Naproxen | rep:1	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-30	pC18-29apr16-030-r002	Group:SED-Naproxen | rep:2	chromatography=PC18
SUBJECT_SAMPLE_FACTORS           	ms5860-1	nhilic-01may16-001-r001	Group:SED-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-1	nhilic-01may16-001-r002	Group:SED-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-2	nhilic-01may16-002-r001	Group:RUN-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-2	nhilic-01may16-002-r002	Group:RUN-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-3	nhilic-01may16-003-r001	Group:RUN-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-3	nhilic-01may16-003-r002	Group:RUN-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-4	nhilic-01may16-004-r001	Group:RUN-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-4	nhilic-01may16-004-r002	Group:RUN-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-5	nhilic-01may16-005-r001	Group:SED-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-5	nhilic-01may16-005-r002	Group:SED-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-6	nhilic-01may16-006-r001	Group:RUN-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-6	nhilic-01may16-006-r002	Group:RUN-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-7	nhilic-01may16-007-r001	Group:SED-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-7	nhilic-01may16-007-r002	Group:SED-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-8	nhilic-01may16-008-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-8	nhilic-01may16-008-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-9	nhilic-01may16-009-r001	Group:SED-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-9	nhilic-01may16-009-r002	Group:SED-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-10	nhilic-01may16-010-r001	Group:SED-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-10	nhilic-01may16-010-r002	Group:SED-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-11	nhilic-01may16-011-r001	Group:RUN-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-11	nhilic-01may16-011-r002	Group:RUN-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-12	nhilic-01may16-012-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-12	nhilic-01may16-012-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-13	nhilic-01may16-013-r001	Group:RUN-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-13	nhilic-01may16-013-r002	Group:RUN-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-14	nhilic-01may16-014-r001	Group:SED-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-14	nhilic-01may16-014-r002	Group:SED-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-15	nhilic-01may16-015-r001	Group:SED-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-15	nhilic-01may16-015-r002	Group:SED-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-16	nhilic-01may16-016-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-16	nhilic-01may16-016-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-17	nhilic-01may16-017-r001	Group:SED-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-17	nhilic-01may16-017-r002	Group:SED-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-18	nhilic-01may16-018-r001	Group:RUN-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-18	nhilic-01may16-018-r002	Group:RUN-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-19	nhilic-01may16-019-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-19	nhilic-01may16-019-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-20	nhilic-01may16-020-r001	Group:RUN-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-20	nhilic-01may16-020-r002	Group:RUN-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-21	nhilic-01may16-021-r001	Group:SED-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-21	nhilic-01may16-021-r002	Group:SED-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-22	nhilic-01may16-022-r001	Group:RUN-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-22	nhilic-01may16-022-r002	Group:RUN-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-23	nhilic-01may16-023-r001	Group:RUN-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-23	nhilic-01may16-023-r002	Group:RUN-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-24	nhilic-01may16-024-r001	Group:RUN-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-24	nhilic-01may16-024-r002	Group:RUN-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-25	nhilic-01may16-025-r001	Group:SED-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-25	nhilic-01may16-025-r002	Group:SED-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-26	nhilic-01may16-026-r001	Group:SED-Naproxcinod | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-26	nhilic-01may16-026-r002	Group:SED-Naproxcinod | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-27	nhilic-01may16-027-r001	Group:SED-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-27	nhilic-01may16-027-r002	Group:SED-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-28	nhilic-01may16-028-r001	Group:SED-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-28	nhilic-01may16-028-r002	Group:SED-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-29	nhilic-01may16-029-r001	Group:SED-Vehicle | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-29	nhilic-01may16-029-r002	Group:SED-Vehicle | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-30	nhilic-01may16-030-r001	Group:SED-Naproxen | rep:1	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-30	nhilic-01may16-030-r002	Group:SED-Naproxen | rep:2	chromatography=NHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-1	philic-29apr16-001-r001	Group:SED-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-1	philic-29apr16-001-r002	Group:SED-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-2	philic-29apr16-002-r001	Group:RUN-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-2	philic-29apr16-002-r002	Group:RUN-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-3	philic-29apr16-003-r001	Group:RUN-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-3	philic-29apr16-003-r002	Group:RUN-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-4	philic-29apr16-004-r001	Group:RUN-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-4	philic-29apr16-004-r002	Group:RUN-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-5	philic-29apr16-005-r001	Group:SED-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-5	philic-29apr16-005-r002	Group:SED-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-6	philic-29apr16-006-r001	Group:RUN-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-6	philic-29apr16-006-r002	Group:RUN-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-7	philic-29apr16-007-r001	Group:SED-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-7	philic-29apr16-007-r002	Group:SED-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-8	philic-29apr16-008-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-8	philic-29apr16-008-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-9	philic-29apr16-009-r001	Group:SED-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-9	philic-29apr16-009-r002	Group:SED-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-10	philic-29apr16-010-r001	Group:SED-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-10	philic-29apr16-010-r002	Group:SED-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-11	philic-29apr16-011-r001	Group:RUN-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-11	philic-29apr16-011-r002	Group:RUN-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-12	philic-29apr16-012-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-12	philic-29apr16-012-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-13	philic-29apr16-013-r001	Group:RUN-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-13	philic-29apr16-013-r002	Group:RUN-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-14	philic-29apr16-014-r001	Group:SED-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-14	philic-29apr16-014-r002	Group:SED-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-15	philic-29apr16-015-r001	Group:SED-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-15	philic-29apr16-015-r002	Group:SED-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-16	philic-29apr16-016-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-16	philic-29apr16-016-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-17	philic-29apr16-017-r001	Group:SED-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-17	philic-29apr16-017-r002	Group:SED-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-18	philic-29apr16-018-r001	Group:RUN-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-18	philic-29apr16-018-r002	Group:RUN-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-19	philic-29apr16-019-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-19	philic-29apr16-019-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-20	philic-29apr16-020-r001	Group:RUN-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-20	philic-29apr16-020-r002	Group:RUN-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-21	philic-29apr16-021-r001	Group:SED-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-21	philic-29apr16-021-r002	Group:SED-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-22	philic-29apr16-022-r001	Group:RUN-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-22	philic-29apr16-022-r002	Group:RUN-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-23	philic-29apr16-023-r001	Group:RUN-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-23	philic-29apr16-023-r002	Group:RUN-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-24	philic-29apr16-024-r001	Group:RUN-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-24	philic-29apr16-024-r002	Group:RUN-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-25	philic-29apr16-025-r001	Group:SED-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-25	philic-29apr16-025-r002	Group:SED-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-26	philic-29apr16-026-r001	Group:SED-Naproxcinod | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-26	philic-29apr16-026-r002	Group:SED-Naproxcinod | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-27	philic-29apr16-027-r001	Group:SED-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-27	philic-29apr16-027-r002	Group:SED-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-28	philic-29apr16-028-r001	Group:SED-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-28	philic-29apr16-028-r002	Group:SED-Naproxen | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-29	philic-29apr16-029-r001	Group:SED-Vehicle | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-29	philic-29apr16-029-r002	Group:SED-Vehicle | rep:2	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-30	philic-29apr16-030-r001	Group:SED-Naproxen | rep:1	chromatography=PHILIC
SUBJECT_SAMPLE_FACTORS           	ms5860-30	philic-29apr16-030-r002	Group:SED-Naproxen | rep:2	chromatography=PHILIC
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood and Tissue Harvesting: Mice will be euthanized and blood will be taken by
CO:COLLECTION_SUMMARY            	cardiac puncture, centrifuged, and the plasma will be stored at -80ºC. The
CO:COLLECTION_SUMMARY            	heart, diaphragm, and muscles of both hindlimbs (gastrocnemius, soleus,
CO:COLLECTION_SUMMARY            	quadriceps) will be dissected and snap frozen in liquid nitrogen. Tibialis
CO:COLLECTION_SUMMARY            	anterior and plantaris muscles from both hindlimbs also will be dissected and
CO:COLLECTION_SUMMARY            	one set will be snap frozen in liquid nitrogen while the other set will be
CO:COLLECTION_SUMMARY            	mounted in OCT and frozen in isopentane cooled by liquid nitrogen. Cryosections
CO:COLLECTION_SUMMARY            	will be used to evaluate disease activity and exercise-induced muscle injury by
CO:COLLECTION_SUMMARY            	staining with: (a) hematoxylin and eosin to assess gross morphology, cellular
CO:COLLECTION_SUMMARY            	infiltration, and necrosis, (b) anti-F4/80 to label macrophages, and (c)
CO:COLLECTION_SUMMARY            	anti-IgG or IgM to label damaged muscle fibers.
#TREATMENT
TR:TREATMENT_SUMMARY             	"Studies will be performed in 12-16 week old male mdx mice, C57BL10 control
TR:TREATMENT_SUMMARY             	mice, and nNOS-/- mice obtained from Jackson Laboratory. All protocols will be
TR:TREATMENT_SUMMARY             	approved by the Penn State College of Medicine Institutional Animal Care and Use
TR:TREATMENT_SUMMARY             	Committee. Drug Treatment: Mice will be treated with vehicle, naproxcinod (20
TR:TREATMENT_SUMMARY             	mg/kg/day) or equimolar naproxen (12.5mg/kg/day) once a day for 7 consecutive
TR:TREATMENT_SUMMARY             	days. To avoid the stress of oral gavage or ip injections in mdx mice, drug or
TR:TREATMENT_SUMMARY             	vehicle will be administered in a small volume of peanut butter. Most mice
TR:TREATMENT_SUMMARY             	readily consume the dosed peanut butter within 30 min. Terminal experiments will
TR:TREATMENT_SUMMARY             	be performed 2 hours after the final dose is consumed."
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	mouse heart untarged metabolomics profiling
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 1290 Infinity
CH:COLUMN_NAME                   	Waters Acquity HSS C18 (150 x 2.1mm, 1.8um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	Agilent 6550 QTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_RESULTS_FILE               	ST000651_AN000985_Results.txt	UNITS:intensity
#END